申请人:Kinoyama Isao
公开号:US20110207729A1
公开(公告)日:2011-08-25
An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT
5A
receptor modulating action.
It was confirmed that a bicyclic acylguanidine derivative which has a characteristic structure that guanidine is bonded to one ring of a bicyclic structure such as chromene and dihydronaphthalene through a carbonyl group and a cyclic group is bonded on the other ring, has a potent 5-HT
5A
receptor modulating action and an excellent pharmacological action based on this mechanism. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.
本发明的目的是提供一种基于血清素5-HT5A受体调节作用的新型优良药剂,用于治疗或预防痴呆症、精神分裂症等疾病。经确认,一种具有特征结构的双环酰基胍衍生物,其中胍基通过羰基和环状基团与类似香豆素和二氢萘的双环结构的一个环相结合,另一个环上结合有一个环状基团,具有强效的5-HT5A受体调节作用和基于该机制的优良药理作用。本发明可用作治疗或预防痴呆症、精神分裂症、双相情感障碍或注意力缺陷多动障碍的优良药剂。